Equity and Noncontrolling Interest

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 23 – Equity and Accumulated Other Comprehensive Loss

The Company has 30,000,000 shares of common stock authorized with a par value of $1, and 17,735,162 and 13,338,026 shares issued and outstanding as of December 31, 2019 and 2018, respectively. The change in shares issued and outstanding during 2019 was primarily related to 4,329,176 shares issued for the Combination, 42,073 shares issued for share-based compensation plans, 3,081 shares issued for the ESPP and 22,806 shares issued for the exercise of stock options and other employee and director-related share activity.

The Company is authorized to issue 10,000,000 shares of preferred stock with $1 par value, subject to approval by the Board of Directors. The Board of Directors may designate one or more series of preferred stock and the number of shares, rights, preferences, and limitations of each series. As of December 31, 2019, no preferred stock had been issued.

The Company has a share repurchase program that was approved by its Board of Directors in 2015 for the repurchase of up to $100.0 million of Quaker Chemical Corporation common stock, which the Company has not used in the three years ended December 31, 2019, 2018, and 2017. As of December 31, 2019, there was approximately $86.9 million of common stock remaining to be purchased under this share repurchase program.

The following table shows the reclassifications from and resulting balances of AOCI for the years ended December 31, 2019, 2018 and 2017:

							Unrealized Gain (Loss) in
					Defined
			Currency		Benefit		Available-for-
			Translation		Pension		Sale			Derivative
			Adjustments		Plans		Securities			Instruments	Total
Balance as of December 31, 2016			$	(52,255)	$	(36,168)	$	1,016	$	—	$	(87,407)
	Other comprehensive income (loss) before
		reclassifications		20,362		(1,646)		2,299		—		21,015
	Amounts reclassified from AOCI			—		5,154		(2,494)		—		2,660
	Related tax amounts			—		(1,433)		65		—		(1,368)
Balance as of December 31, 2017				(31,893)		(34,093)		886		—		(65,100)
	Other comprehensive (loss) income before
		reclassifications		(17,429)		1,543		(2,622)		—		(18,508)
	Amounts reclassified from AOCI			—		3,085		435		—		3,520
	Related tax amounts			—		(1,086)		459		—		(627)
Balance as of December 31, 2018				(49,322)		(30,551)		(842)		—		(80,715)
	Other comprehensive income (loss) before
		reclassifications		4,754		(8,088)		2,951		(415)		(798)
	Amounts reclassified from AOCI			—		3,169		(301)		—		2,868
	Related tax amounts			—		937		(557)		95		475
Balance as of December 31, 2019			$	(44,568)	$	(34,533)	$	1,251	$	(320)	$	(78,170)

All reclassifications related to unrealized gain (loss) in available-for-sale securities relate to the Company’s equity interest in Primex, a captive insurance company and are recorded in equity in net income of associated companies. The amounts reported on the Consolidated Statements of Changes in Equity for non-controlling interest are related to currency translation adjustments.